2024
Molecular MR Imaging of T-Cell Immune Response to Cryoablation in Immunologically Hot vs. Cold Hepatocellular Carcinoma.
Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MR Imaging of T-Cell Immune Response to Cryoablation in Immunologically Hot vs. Cold Hepatocellular Carcinoma. JHEP Reports 2024, 101294. DOI: 10.1016/j.jhepr.2024.101294.Peer-Reviewed Original ResearchT cell infiltrationHepatocellular carcinomaRadiological-pathological correlationImaging mass cytometryImmune responseT1-weighted MRITumor-infiltrating CD8+ T lymphocytesAnti-tumor immune responseCD8+ T lymphocytesIncreased T lymphocyte infiltrationImaging biomarkersNon-immunogenic tumorsSystemic lymph nodesT lymphocyte infiltrationMurine tumor modelsImmune cell typesLocal tumor therapyPrimary liver cancerNon-invasive imaging biomarkerTesla MRI scannerInduce liver cirrhosisImmunogenic tumorsLocoregional therapySystemic immunotherapyHCC lesions
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2013
Percutaneous therapies of hepatocellular carcinoma—an update
Chapiro J, Geschwind JF. Percutaneous therapies of hepatocellular carcinoma—an update. Chinese Clinical Oncology 2013, 2: 36-36. PMID: 25841915, DOI: 10.3978/j.issn.2304-3865.2013.07.04.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaSpecific therapeutic algorithmsAvailable clinical evidenceEarly-stage diseaseIntra-arterial approachEnd-stage diseaseLocal tumor controlPrimary liver cancerTreatment of patientsTherapeutic algorithmEthanol ablationTransarterial chemoembolizationClinical evidencePatient groupTumor controlPercutaneous techniquesRadiofrequency ablationSuch therapyTherapeutic spectrumAblative techniquesPercutaneous therapyLiver cancerSystemic toxicityTherapyIntraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization